HY-033

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameHY-033
Drug Alias NameHY-033HY033
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionT lymphocyte replacementsGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJuventas Cell Therapy Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJuventas Cell Therapy Ltd
Inactive CompaniesN/A
Active IndicationsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A